Table 2.
Baseline characteristics after propensity matching score analysis.
| G1 n = 92 |
G2 n = 92 |
p-Value | |
|---|---|---|---|
| Age (±SD) | 71.2 ± 13 | 72.6 ± 11.5 | 0.42 |
| Female Gender, n (%) | 27 (29.3) | 31 (33.7) | 0.53 |
| Arterial hypertension, n (%) | 73 (79.3) | 72 (78.3) | 0.85 |
| Diabetes mellitus, n (%) | 28 (30.4) | 28 (30.4) | 1 |
| Dyslipidemia, n (%) | 65 (70.7) | 59 (64.1) | 0.35 |
| Smoking habit, n (%) | 52 (56.5) | 53 (57.6) | 0.89 |
| Familiarity for CVD, n (%) | 47 (51.1) | 47 (51.1) | 1 |
| Creatinine Clearance, mL/min (±SD) | 66.6 ± 25.1 | 68.5 ± 22.5 | 0.60 |
| Ischemic HF etiology, n (%) | 46 (50) | 54 (59) | 0.30 |
| HFpEF, n (%) | 43 (47) | 48 (52) | 0.55 |
| HFmrEF, n (%) | 16 (17) | 15 (16) | 1 |
| HFrEF, n (%) | 33 (36) | 29 (32) | 0.64 |
| LV EDD, mm (±SD) | 53.3 ± 7.6 | 54 ± 6.6 | 0.5 |
| IVS, mm (±SD) | 11.35 ± 1.75 | 11.54 ± 1.72 | 0.46 |
| PW, mm (±SD) | 10.2 ±1.5 | 10 ± 1.36 | 0.34 |
| LVEF, % (±SD) | 47 ± 11 | 48 ± 10 | 0.76 |
| TAPSE, mm (±SD) | 18 ± 4 | 17 ± 4 | 0.09 |
| PAPs, mmHg (±SD) | 40 ± 11 | 37.5 ± 13 | 0.16 |
| E/e’ ratio (±SD) | 9 ± 2 | 9.5 ± 2.2 | 0.11 |
| BB, n (%) | 80 (87) | 74 (81) | 0.32 |
| ACE-i/ARBs, n (%) | 63 (68) | 66 (72) | 0.75 |
| ARNI, n (%) | 23 (25) | 13 (14) | 0.09 |
| MRAs, n (%) | 47 (51) | 52 (57) | 0.55 |
| Loop diuretics, n (%) | 64 (70) | 51 (55) | 0.07 |
| MAGGIC Score | 20 ± 7.2 | 20 ± 7.8 | 0.72 |
CVD: cardiovascular diseases; HF: heart failure; HFpEF: heart failure with preserved ejection fraction; HFmrEF: heart failure with mildly reduced ejection fraction; HFrEF: heart failure with reduced ejection fraction; LV EDD: left ventricular end-diastolic diameter; IVS: interventricular septum; PW: posterior wall; LVEF: left ventricular ejection fraction; TAPSE: tricuspid annular plane systolic excursion; PAPs: pulmonary artery systolic pressure; BB: betablockers; ACE-i/ARBs: angiotensin-converting enzyme inhibitors/angiotensin receptor blockers; ARNI: angiotensin receptor-neprilysin inhibitor; MRAs: mineralocorticoid receptor antagonists; MAGGIC: meta-analysis global group in chronic heart failure.